Navigation Links
Forward Expeditions to Promote CaringBridge(R) on Historic Victorinox North Pole '09 Expedition
Date:11/20/2008

EAGAN, Minn., Nov. 20 /PRNewswire/ -- Forward Expeditions LLC, Ely, Minn., announced today that they will use their upcoming historic Victorinox North Pole expedition to raise awareness and funds for CaringBridge(R), a Minnesota-based nonprofit organization offering free personalized Web sites to people facing serious medical conditions. The world's largest charitable nonprofit Web site, CaringBridge connects more than 20 million families each year through personal, private CaringBridge Web sites. In addition to raising awareness, expedition team members are hopeful that their unique approach to the expedition's physical and mental challenges will also inspire the families using and supporting CaringBridge.

The Victorinox North Pole '09 expedition team of John Huston and Tyler Fish will attempt to become the first Americans to ski unsupported to the North Pole. Huston, age 32 of Chicago, Ill., and Fish, age 34 of Ely, Minn., will depart from the northern tip of Canada's Ellesmere Island in early March 2009 and trek 475 miles over the Arctic Ocean to the North Pole. Their expedition will not receive or use any outside assistance such as airdrops, re-supplies or sled dogs. Instead, Huston and Fish will each carry 30-pound packs and pull 250-pound sleds full of gear, food, cooking fuel and navigational equipment as they negotiate the maze of ice ridges, drifts and open water that stand between them and the Pole. Huston and Fish will travel by skiing and snowshoeing, and when necessary will cross leads by swimming, while wearing dry suits.

"The extremely rugged terrain and bitter cold of the Arctic Ocean make this particular expedition very dangerous and intimidating, and if we lose our focus we could become overwhelmed," says Huston. "We believe that by approaching this challenge with optimism, humility and responsible action, we can be successful and safely reach the Pole."

As they began preparing fo
'/>"/>

SOURCE CaringBridge
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Elementary School Students to Launch Kids for Sight Campaign, to Inspire Other Kids to Pay it Forward
2. COLORBLENDS to Donate Portion of Sales of Spring Forward Daffodil Blend to the Christopher and Dana Reeve Foundation
3. Bond Laboratories, Inc. Announces 2-for-1 Forward Split
4. Federal Judge Says Sugar Association Suit Accusing Johnson & Johnson of False Advertising to Go Forward
5. Light and sound -- the way forward for better medical imaging
6. ESA and EC take major step forward in GMES
7. Congressional Budget Includes Earmark to Keep Washingtons Sexual Assault DNA Program Moving Forward
8. AARP Urges Senate to Move Forward on Health Care Reform
9. Natural Nutrition Announces Forward Split of Common Stock
10. New Fashion-Forward Footwear from Aetrex Offers Patented Customization to Help Eliminate Foot Pain
11. Natural Nutrition Announces Effectiveness of Forward Split of Common Stock Following 2007 Record Revenue Year
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Maxygen, Inc. Announces Extension of Dutch Auction Tender Offer 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Interleukin Genetics to Present Research Linking Perilipin Genes to Diet Response at the ADA Annual Meeting 48082 1Interleukin Genetics to Present Research Linking Perilipin Genes to Diet Response at the ADA Annual Meeting 48082 2Interleukin Genetics to Present Research Linking Perilipin Genes to Diet Response at the ADA Annual Meeting 48082 3Researchers Uncover Why Turmeric Helps Heal 48078 1Chandler Chicco Companies Announces New Brandtectonics Access US Offering 48073 1Chandler Chicco Companies Announces New Brandtectonics Access US Offering 48073 2Chandler Chicco Companies Announces New Brandtectonics Access US Offering 48073 3